AIFF — Firefly Neuroscience Balance Sheet
0.000.00%
- $37.19m
- $36.08m
- $0.11m
Annual balance sheet for Firefly Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 1.86 | 4.93 | 0.731 | 0.682 | 1.81 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.44 | 1.66 | 1.63 | 1.12 | 0.121 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3.44 | 6.87 | 2.8 | 2.07 | 2.63 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.114 | 0.778 | 0.974 | 0.304 | 0.136 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 3.77 | 23.4 | 7.98 | 4.52 | 4.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.8 | 1.98 | 3.89 | 2.1 | 4.98 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.16 | 5.92 | 4.25 | 2.25 | 4.98 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 1.61 | 17.4 | 3.73 | 2.27 | -0.375 |
Total Liabilities & Shareholders' Equity | 3.77 | 23.4 | 7.98 | 4.52 | 4.6 |
Total Common Shares Outstanding |